

Rowan T Chlebowski

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4412699/rowan-t-chlebowski-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

363
papers

31,129
citations

76
h-index

171
g-index

381
ext. papers

35,221
ext. citations

8.2
avg, IF

6.56
L-index

| # | Paper | IF | Citations |
|-----|--|-----|-----------|
| 363 | Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women's Health Initiative.. <i>BMC Women's Health</i> , 2022 , 22, 32 | 2.9 | 0 |
| 362 | Reply to the siren's song of anonymous web-based sampling.. <i>Cancer</i> , 2022 , | 6.4 | |
| 361 | Breast Cancer Prevention and Breast Cancer Mortality.. <i>JCO Oncology Practice</i> , 2022 , OP2200091 | 2.3 | 1 |
| 360 | A Coala-T-Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment. <i>Cancer</i> , 2021 , | 6.4 | 4 |
| 359 | Nutritional epidemiology and the Women's Health Initiative: a review. <i>American Journal of Clinical Nutrition</i> , 2021 , 113, 1083-1092 | 7 | 1 |
| 358 | Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women's Health Initiative (WHI) randomised trial. <i>British Journal of Cancer</i> , 2021 , 125, 372-379 | 8.7 | 2 |
| 357 | Low-Fat Dietary Modification and Risk of Ductal Carcinoma of the Breast in the Women's Health Initiative Dietary Modification Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1753-1756 ⁴ | | 0 |
| 356 | A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab072 | 4.6 | 0 |
| 355 | Breast Cancer Prevention: Time for Change. <i>JCO Oncology Practice</i> , 2021 , 17, 709-716 | 2.3 | 6 |
| 354 | Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative. <i>Cancer</i> , 2021 , 127, 598-608 | 6.4 | 5 |
| 353 | Reply to The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data. <i>Cancer</i> , 2021 , 127, 813-814 | 6.4 | |
| 352 | Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age. <i>American Journal of Epidemiology</i> , 2021 , 190, 365-375 | 3.8 | 10 |
| 351 | Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. <i>Cancer</i> , 2021 , 127, 1658-1667 | 6.4 | 0 |
| 350 | Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. <i>Cancer</i> , 2021 , 127, 3742-3750 | 6.4 | 2 |
| 349 | Sleep medication use and risk of fractures in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 541-548 | 4.4 | 0 |
| 348 | Prentice et al. Respond to "Studying Co-Occurrence of Multiple Outcomes". <i>American Journal of Epidemiology</i> , 2020 , 189, 985-986 | 3.8 | |
| 347 | Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative. <i>Oncologist</i> , 2020 , 25, 712-721 | 5.7 | 0 |

| | | | |
|-----|---|------|----|
| 346 | Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women's Health Initiative. <i>Cancer</i> , 2020 , 126, 3638-3647 | 6.4 | 14 |
| 345 | Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. <i>Cancer</i> , 2020 , 126, 2956-2964 | 6.4 | 7 |
| 344 | Association of Diet Quality and Physical Activity on Obesity-Related Cancer Risk and Mortality in Black Women: Results from the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 591-598 | 4 | 2 |
| 343 | Dietary Moderation and Deaths From Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3071-3072 | 2.2 | 3 |
| 342 | Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1419-1428 | 2.2 | 37 |
| 341 | Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls. <i>Breast Cancer Research and Treatment</i> , 2020 , 180, 767-775 | 4.4 | 0 |
| 340 | The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2020 , 180, 747-757 | 4.4 | 6 |
| 339 | Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial. <i>EClinicalMedicine</i> , 2020 , 18, 100240 | 11.3 | 3 |
| 338 | Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. <i>American Journal of Epidemiology</i> , 2020 , 189, 972-981 | 3.8 | 4 |
| 337 | Protein Intake by Source and Breast Cancer Incidence and Mortality: The Women's Health Initiative. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa101 | 4.6 | 2 |
| 336 | Online Health Information-Seeking Among Older Women With Chronic Illness: Analysis of the Women's Health Initiative. <i>Journal of Medical Internet Research</i> , 2020 , 22, e15906 | 7.6 | 14 |
| 335 | Postmenopausal Breast Cancer and Physical Function Change: A Difference-in-Differences Analysis. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 1029-1036 | 5.6 | 1 |
| 334 | The association between DXA-derived body fat measures and breast cancer risk among postmenopausal women in the Women's Health Initiative. <i>Cancer Medicine</i> , 2020 , 9, 1581-1599 | 4.8 | 4 |
| 333 | Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?. <i>Breast Journal</i> , 2020 , 26, 2199-2202 | 1.3 | 2 |
| 332 | Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers. <i>JAMA Network Open</i> , 2020 , 3, e207227 | 10.4 | 11 |
| 331 | Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 369-380 | 27.4 | 85 |
| 330 | Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4687-4694 | 3.1 | 8 |
| 329 | Risk of Breast Cancer Associated with Estrogen DNA Adduct Biomarker. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2096-2099 | 4 | |

| | | | |
|-----|---|------|-----|
| 328 | Insulin Resistance and Cancer-Specific and All-Cause Mortality in Postmenopausal Women: The Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 170-178 | 9.7 | 13 |
| 327 | Genetic Predictors of Circulating 25-Hydroxyvitamin D and Prognosis after Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1128-1134 | 4 | |
| 326 | Intentional Weight Loss and Obesity-Related Cancer Risk. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz054 | 4.6 | 40 |
| 325 | Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 785-794 | 4.4 | 22 |
| 324 | Reply to F. Conforti et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1840-1841 | 2.2 | |
| 323 | Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes. <i>Journal of Nutrition</i> , 2019 , 149, 1565-1574 | 4.1 | 17 |
| 322 | Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 858-861 | 2.2 | 5 |
| 321 | Association of Normal-Weight Central Obesity With All-Cause and Cause-Specific Mortality Among Postmenopausal Women. <i>JAMA Network Open</i> , 2019 , 2, e197337 | 10.4 | 62 |
| 320 | Low-fat dietary pattern and breast cancer mortality by metabolic syndrome degree: Secondary analyses of the Women's Health Initiative (WHI) Dietary Modification randomized trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1539-1539 | 2.2 | 1 |
| 319 | Weight loss, diet composition and breast cancer incidence and outcome in postmenopausal women. <i>Oncotarget</i> , 2019 , 10, 3088-3092 | 3.3 | 6 |
| 318 | Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2019 , 171, 406-414 | 8 | 19 |
| 317 | Physical activity and weight gain after smoking cessation in postmenopausal women. <i>Menopause</i> , 2019 , 26, 16-23 | 2.5 | 4 |
| 316 | Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. <i>International Journal of Cancer</i> , 2019 , 144, 730-740 | 7.5 | 3 |
| 315 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019 , 104, 21-34 | 11 | 363 |
| 314 | Adiposity, history of diabetes, and risk of pancreatic cancer in postmenopausal women. <i>Annals of Epidemiology</i> , 2019 , 29, 23-29.e1 | 6.4 | 1 |
| 313 | Racial and Ethnic Differences in Anthropometric Measures as Risk Factors for Diabetes. <i>Diabetes Care</i> , 2019 , 42, 126-133 | 14.6 | 21 |
| 312 | Interaction of body mass index or waist-to-hip ratio and sun exposure associated with nonmelanoma skin cancer: A prospective study from the Women's Health Initiative. <i>Cancer</i> , 2019 , 125, 1133-1142 | 6.4 | 3 |
| 311 | Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. <i>JAMA Oncology</i> , 2019 , 5, 155-163 | 13.4 | 92 |

| | | | |
|-----|---|-----|----|
| 310 | Weight loss and breast cancer incidence in postmenopausal women. <i>Cancer</i> , 2019 , 125, 205-212 | 6.4 | 37 |
| 309 | Serum glucose and insulin and risk of cancers of the breast, endometrium, and ovary in postmenopausal women. <i>European Journal of Cancer Prevention</i> , 2018 , 27, 261-268 | 2 | 23 |
| 308 | Postmenopausal Fracture History and Survival After Reproductive Cancer Diagnosis. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky001 | 4.6 | 1 |
| 307 | Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. <i>Cancer</i> , 2018 , 124, 1798-1807 | 6.4 | 27 |
| 306 | 36-Item Short Form Survey (SF-36) Versus Gait Speed As Predictor of Preclinical Mobility Disability in Older Women: The Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2018 , 66, 706-713 | 5.6 | 10 |
| 305 | Post-Stroke Cancer Risk among Postmenopausal Women: The Women's Health Initiative. <i>Women's Health Issues</i> , 2018 , 28, 29-34 | 2.6 | 2 |
| 304 | Breast cancer survivorship: state of the science. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 593-604 | 4.4 | 6 |
| 303 | Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials. <i>American Heart Journal</i> , 2018 , 198, 108-114 | 4.9 | 1 |
| 302 | Emerging combination endocrine therapies for advanced breast cancer. <i>Breast Journal</i> , 2018 , 24, 214-215 | 2 | |
| 301 | Association of Cataract Surgery With Mortality in Older Women: Findings from the Women's Health Initiative. <i>JAMA Ophthalmology</i> , 2018 , 136, 3-10 | 3.9 | 21 |
| 300 | Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2018 , 110, | 9.7 | 27 |
| 299 | Stratified Probabilistic Bias Analysis for Body Mass Index-related Exposure Misclassification in Postmenopausal Women. <i>Epidemiology</i> , 2018 , 29, 604-613 | 3.1 | 12 |
| 298 | Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 145-147 | 4.5 | 6 |
| 297 | Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative (WHI).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13567-e13567 | 2.2 | 3 |
| 296 | Trajectory of recurrent falls in postmenopausal breast cancer survivors and matched cancer-free controls.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e22100-e22100 | 2.2 | |
| 295 | A comprehensive evaluation of breast cancer treatment delays by race among Women's Health Initiative participants.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18579-e18579 | 2.2 | |
| 294 | Low-fat dietary pattern and all cancer mortality in the Women's Health Initiative (WHI) randomized trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1500-1500 | 2.2 | |
| 293 | Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. <i>Menopause</i> , 2018 , 26, 578-587 | 2.5 | 7 |

| | | | |
|-----|---|------|-----|
| 292 | Serum lipids and risk of obesity-related cancers in postmenopausal women. <i>Cancer Causes and Control</i> , 2018 , 29, 13-24 | 2.8 | 17 |
| 291 | Complexity of intermittent letrozole adjuvant therapy. <i>Lancet Oncology, The</i> , 2018 , 19, 13-15 | 21.7 | |
| 290 | Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i> , 2018 , 25, 11-20 | 2.5 | 103 |
| 289 | Association between Dietary Energy Density and Obesity-Associated Cancer: Results from the Women's Health Initiative. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2018 , 118, 617-626 | 3.9 | 9 |
| 288 | Low-Fat Dietary Pattern and Cancer Mortality in the Women's Health Initiative (WHI) Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky065 | 4.6 | 9 |
| 287 | Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured Women. <i>Ethnicity and Disease</i> , 2018 , 28, 565-574 | 1.8 | 7 |
| 286 | Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative. <i>PLoS ONE</i> , 2018 , 13, e0207509 | 3.7 | 7 |
| 285 | Notice of Retraction and Replacement. Tseng et al. Association of cataract surgery with mortality in older women: findings from the Women's Health Initiative. <i>JAMA Ophthalmol.</i> 2018;136(1):3-10. <i>JAMA Ophthalmology</i> , 2018 , 136, 1313-1314 | 3.9 | 2 |
| 284 | Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e181212 | 13.4 | 40 |
| 283 | Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. <i>Menopause</i> , 2018 , 25, 985-991 | 2.5 | 12 |
| 282 | Intentional Weight Loss and Endometrial Cancer Risk. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1189-1193 | 2.2 | 53 |
| 281 | Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 629-635 | 2.2 | 10 |
| 280 | Prediagnostic Calcium Intake and Lung Cancer Survival: A Pooled Analysis of 12 Cohort Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1060-1070 | 4 | 7 |
| 279 | Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2017 , 65, 1924-1931 | 5.6 | 6 |
| 278 | Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2017 , 109, | 9.7 | 63 |
| 277 | Sex Steroid Hormones and Fracture in a Multiethnic Cohort of Women: The Women's Health Initiative Study (WHI). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1538-1547 | 5.6 | 12 |
| 276 | Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. <i>Cancer</i> , 2017 , 123, 3107-3115 | 6.4 | 25 |
| 275 | Response. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 633-634 | 4.4 | |

| | | | |
|-----|---|------|-----|
| 274 | Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. <i>Journal of the National Cancer Institute</i> , 2017 , 109, | 9.7 | 31 |
| 273 | Sedentary time and postmenopausal breast cancer incidence. <i>Cancer Causes and Control</i> , 2017 , 28, 1405-1416 | 1.8 | 8 |
| 272 | Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1730-1735 | 4 | 45 |
| 271 | Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women. <i>Cancer Causes and Control</i> , 2017 , 28, 1053-1063 | 2.8 | 4 |
| 270 | Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. <i>Cancers</i> , 2017 , 9, | 6.6 | 15 |
| 269 | Post-diagnosis body mass index and mortality among women diagnosed with endometrial cancer: Results from the Women's Health Initiative. <i>PLoS ONE</i> , 2017 , 12, e0171250 | 3.7 | 7 |
| 268 | Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2919-2926 | 2.2 | 66 |
| 267 | Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative. <i>International Journal of Cancer</i> , 2017 , 141, 2281-2290 | 7.5 | 11 |
| 266 | Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 927-938 | 27.4 | 268 |
| 265 | Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. <i>Menopause</i> , 2017 , 24, 133-141 | 2.5 | 9 |
| 264 | Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1345-1348 | 4 | 10 |
| 263 | Lifestyle and Breast Cancer 2017 , 831-839 | | |
| 262 | Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 185-190 | 4.4 | 13 |
| 261 | Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative. <i>PLoS ONE</i> , 2017 , 12, e0184174 | 3.7 | 42 |
| 260 | Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index. <i>Journal of the National Cancer Institute</i> , 2016 , 108, | 9.7 | 22 |
| 259 | Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 547-562 | 4.4 | 5 |
| 258 | Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial. <i>International Journal of Cancer</i> , 2016 , 138, 604-11 | 7.5 | 12 |
| 257 | Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 567-576 | 4.4 | 4 |

| | | | |
|-----|--|------|-----|
| 256 | Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2899-905 | 2.2 | 30 |
| 255 | Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016 , 115, 129-35 | 8.7 | 64 |
| 254 | Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. <i>Clinical Lung Cancer</i> , 2016 , 17, 10-7.e1 | 4.9 | 25 |
| 253 | Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older. <i>Journal of the National Cancer Institute</i> , 2016 , 108, | 9.7 | 13 |
| 252 | Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. <i>Journal of Clinical Oncology</i> , 2016 , 34, 360-8 | 2.2 | 24 |
| 251 | Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative. <i>International Journal of Cancer</i> , 2016 , 138, 1915-27 | 7.5 | 30 |
| 250 | Pet Ownership and Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1311-6 | 4 | 8 |
| 249 | Obesity and Cancer: Insights for Clinicians. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4197-4202 | 2.2 | 25 |
| 248 | Weight Loss Randomized Intervention Trials in Female Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4238-4248 | 2.2 | 49 |
| 247 | Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4249-4255 | 2.2 | 55 |
| 246 | Alcohol Use and Breast Cancer Survival among Participants in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1268-73 | 4 | 12 |
| 245 | Cardiovascular Disease After Aromatase Inhibitor Use. <i>JAMA Oncology</i> , 2016 , 2, 1590-1597 | 13.4 | 54 |
| 244 | Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016 , 114, 1277-85 | 8.7 | 66 |
| 243 | Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. <i>International Journal of Cancer</i> , 2016 , 139, 2178-92 | 7.5 | 20 |
| 242 | Statins and breast cancer stage and mortality in the Women's Health Initiative. <i>Cancer Causes and Control</i> , 2015 , 26, 529-39 | 2.8 | 39 |
| 241 | Oral bisphosphonate use and risk of postmenopausal endometrial cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1186-90 | 2.2 | 14 |
| 240 | Interpreting quality-of-life data from the SOFT and TEXT trials. <i>Lancet Oncology</i> , 2015 , 16, 749-51 | 21.7 | 6 |
| 239 | Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA Oncology</i> , 2015 , 1, 611-21 | 13.4 | 294 |

| | | | |
|-----|---|------|-----|
| 238 | Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. <i>Cancer</i> , 2015 , 121, 2147-55 | 6.4 | 35 |
| 237 | Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. <i>JAMA Oncology</i> , 2015 , 1, 296-305 | 13.4 | 141 |
| 236 | Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015 , 107, | 9.7 | 69 |
| 235 | Menopausal hormone therapy and breast cancer mortality: clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2015 , 6, 45-56 | 3.5 | 24 |
| 234 | SNPs and breast cancer risk prediction for African American and Hispanic women. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 583-9 | 4.4 | 35 |
| 233 | Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 609-16 | 4.4 | 16 |
| 232 | Relationships between dog ownership and physical activity in postmenopausal women. <i>Preventive Medicine</i> , 2015 , 70, 33-8 | 4.3 | 32 |
| 231 | Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1004-13 | 8.9 | 33 |
| 230 | Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 917-24 | 7.3 | 15 |
| 229 | Estrogen and colorectal cancer incidence and mortality. <i>Cancer</i> , 2015 , 121, 3261-71 | 6.4 | 24 |
| 228 | Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. <i>Journal of Cancer Epidemiology</i> , 2015 , 2015, 203284 | 2.8 | 3 |
| 227 | Association Between Obesity and Postmenopausal Breast Cancer Risk-Reply. <i>JAMA Oncology</i> , 2015 , 1, 1171 | 13.4 | |
| 226 | Metformin and breast and gynecological cancer risk among women with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2015 , 3, e000049 | 4.5 | 22 |
| 225 | IBIS-I tamoxifen update: maturity brings questions. <i>Lancet Oncology</i> , 2015 , 16, 7-9 | 21.7 | 31 |
| 224 | Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. <i>Cancer Causes and Control</i> , 2015 , 26, 219-229 | 2.8 | 36 |
| 223 | Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative. <i>Gynecologic Oncology</i> , 2014 , 133, 4-10 | 4.9 | 50 |
| 222 | Birth weight and subsequent risk of cancer. <i>Cancer Epidemiology</i> , 2014 , 38, 538-43 | 2.8 | 38 |
| 221 | Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1427-36 | 2.2 | 40 |

| | | | |
|-----|--|------|-----|
| 220 | Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. <i>Cancer Prevention Research</i> , 2014 , 7, 378-87 | 3.2 | 115 |
| 219 | Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative. <i>Cancer Prevention Research</i> , 2014 , 7, 42-53 | 3.2 | 140 |
| 218 | Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. <i>Breast Cancer Research</i> , 2014 , 16, R30 | 8.3 | 19 |
| 217 | Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. <i>Steroids</i> , 2014 , 90, 53-9 | 2.8 | 27 |
| 216 | Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. <i>Annals of Internal Medicine</i> , 2014 , 160, 594-602 | 8 | 36 |
| 215 | Reply to P. Niravath et Al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3780-1 | 2.2 | |
| 214 | Dietary cadmium exposure and risk of breast, endometrial, and ovarian cancer in the Women's Health Initiative. <i>Environmental Health Perspectives</i> , 2014 , 122, 594-600 | 8.4 | 71 |
| 213 | Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer. <i>Clinical Investigation</i> , 2014 , 4, 19-33 | | 5 |
| 212 | Walking speed, physical activity, and breast cancer in postmenopausal women. <i>European Journal of Cancer Prevention</i> , 2014 , 23, 49-52 | 2 | 5 |
| 211 | Cancer incidence and mortality during the intervention and postintervention periods of the Women's Health Initiative dietary modification trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2924-35 | 4 | 36 |
| 210 | Hormone therapy use and outcomes in the Women's Health Initiative trials--reply. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 417-8 | 27.4 | 2 |
| 209 | Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. <i>Obstetrical and Gynecological Survey</i> , 2014 , 69, 83-85 | 2.4 | 3 |
| 208 | Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer. <i>Clinical Breast Cancer</i> , 2014 , 14, 147-53 | 3 | 17 |
| 207 | Current concepts in breast cancer chemoprevention. <i>Polish Archives of Internal Medicine</i> , 2014 , 124, 191-9 | 2.9 | 6 |
| 206 | Racial/ethnic variations in lung cancer incidence and mortality, adjusted for smoking behavior: Results from the Women's Health Initiative.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1528-1528 | 2.2 | |
| 205 | Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 461-8 | 4.4 | 23 |
| 204 | Frequency of private spiritual activity and cardiovascular risk in postmenopausal women: the Women's Health Initiative. <i>Annals of Epidemiology</i> , 2013 , 23, 239-45 | 6.4 | 15 |
| 203 | Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 1353-68 | 27.4 | 811 |

| | | | |
|-----|---|-----|-----|
| 202 | Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. <i>Journal of Women's Health</i> , 2013 , 22, 915-29 | 3 | 73 |
| 201 | Calcium plus vitamin D supplementation and joint symptoms in postmenopausal women in the women's health initiative randomized trial. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2013 , 113, 1302-10 | 3.9 | 12 |
| 200 | Investigating the association of lactation history and postmenopausal breast cancer risk in the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2013 , 65, 969-81 | 2.8 | 5 |
| 199 | Sex hormone levels and risk of breast cancer with estrogen plus progestin. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1496-503 | 9.7 | 26 |
| 198 | Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. <i>Cancer Epidemiology</i> , 2013 , 37, 742-9 | 2.8 | 46 |
| 197 | Nutrition and physical activity influence on breast cancer incidence and outcome. <i>Breast</i> , 2013 , 22 Suppl 2, S30-7 | 3.6 | 82 |
| 196 | Body mass index, physical activity, and survival after endometrial cancer diagnosis: results from the Women's Health Initiative. <i>Gynecologic Oncology</i> , 2013 , 128, 181-6 | 4.9 | 42 |
| 195 | Changing concepts of hormone receptor-positive advanced breast cancer therapy. <i>Clinical Breast Cancer</i> , 2013 , 13, 159-66 | 3 | 22 |
| 194 | Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women. <i>Cancer Causes and Control</i> , 2013 , 24, 577-85 | 2.8 | 20 |
| 193 | Prospective analysis of association between statin use and breast cancer risk in the women's health initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1868-76 | 4 | 35 |
| 192 | Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings. <i>Journal of Family Planning and Reproductive Health Care</i> , 2013 , 39, 226-8 | | |
| 191 | Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 365-73 | 4 | 21 |
| 190 | Regression calibration in nutritional epidemiology: example of fat density and total energy in relationship to postmenopausal breast cancer. <i>American Journal of Epidemiology</i> , 2013 , 178, 1663-72 | 3.8 | 24 |
| 189 | Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005. <i>Cancer Medicine</i> , 2013 , 2, 526-36 | 4.8 | 6 |
| 188 | Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 2043-8 | 6.3 | 13 |
| 187 | Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer. <i>Breast Journal</i> , 2013 , 19, 552-4 | 1.2 | 2 |
| 186 | Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 526-35 | 9.7 | 143 |
| 185 | Reply to S. Gandini et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 974-5 | 2.2 | 1 |

| | | | |
|-----|---|------|-----|
| 184 | Vitamin D intake and lung cancer risk in the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2013 , 98, 1002-11 | 7 | 39 |
| 183 | Association between sleep and breast cancer incidence among postmenopausal women in the Women's Health Initiative. <i>Sleep</i> , 2013 , 36, 1437-44 | 1.1 | 52 |
| 182 | Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. <i>Menopause</i> , 2013 , 20, 600-8 | 2.5 | 31 |
| 181 | Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2012 , 97, 22-8 | 3.7 | 7 |
| 180 | Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 969-79 | 4.4 | 21 |
| 179 | Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 275-85 | 4.4 | 43 |
| 178 | Fine mapping of 14q24.1 breast cancer susceptibility locus. <i>Human Genetics</i> , 2012 , 131, 479-90 | 6.3 | 5 |
| 177 | Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. <i>Lancet Oncology</i> , 2012 , 13, 476-86 | 21.7 | 262 |
| 176 | Metformin and breast cancer risk: a meta-analysis and critical literature review. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 639-46 | 4.4 | 156 |
| 175 | Recreational physical activity, body mass index, and survival in women with colorectal cancer. <i>Cancer Causes and Control</i> , 2012 , 23, 1939-48 | 2.8 | 90 |
| 174 | Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors. <i>Breast Journal</i> , 2012 , 18, 299-302 | 1.2 | 0 |
| 173 | Clinical Perspective: Influence of Modifiable Lifestyle Factors, Body Weight, Physical Activity, and Alcohol on Breast Cancer Outcome. <i>Current Breast Cancer Reports</i> , 2012 , 4, 188-198 | 0.8 | |
| 172 | Birth weight, breast cancer and the potential mediating hormonal environment. <i>PLoS ONE</i> , 2012 , 7, e40199 | 5.7 | 32 |
| 171 | Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 375-85 | 4.4 | 45 |
| 170 | Diabetes, metformin, and breast cancer in postmenopausal women. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2844-52 | 2.2 | 151 |
| 169 | Diabetes and lung cancer among postmenopausal women. <i>Diabetes Care</i> , 2012 , 35, 1485-91 | 14.6 | 28 |
| 168 | Changing concepts: Menopausal hormone therapy and breast cancer. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 517-27 | 9.7 | 105 |
| 167 | Vitamin D and calcium supplementation and one-year change in mammographic density in the women's health initiative calcium and vitamin D trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 462-73 | 4 | 19 |

| | | | |
|-----|---|------|-----|
| 166 | Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1203-12 | 4.2 | 43 |
| 165 | Estrogen plus progestin and colorectal cancer incidence and mortality. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3983-90 | 2.2 | 75 |
| 164 | Adipokines linking obesity with colorectal cancer risk in postmenopausal women. <i>Cancer Research</i> , 2012 , 72, 3029-37 | 10.1 | 114 |
| 163 | Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 2022-32 | 4 | 10 |
| 162 | Caution in reinterpreting the Women's Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results. <i>American Journal of Clinical Nutrition</i> , 2012 , 95, 258-9; author reply 259 | 7 | 9 |
| 161 | Bisphosphonates and breast cancer prevention. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012 , 12, 144-50 | 5.0 | 15 |
| 160 | Diabetes, metformin use, and colorectal cancer survival in women: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14005-e14005 | 2.2 | 4 |
| 159 | The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. <i>Nutrition and Cancer</i> , 2011 , 63, 827-41 | 2.8 | 68 |
| 158 | Exemestane for breast-cancer prevention in postmenopausal women. <i>New England Journal of Medicine</i> , 2011 , 364, 2381-91 | 59.2 | 705 |
| 157 | 25-hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women. <i>Maturitas</i> , 2011 , 68, 73-8 | 5 | 22 |
| 156 | Vitamin D and breast cancer: interpreting current evidence. <i>Breast Cancer Research</i> , 2011 , 13, 217 | 8.3 | 44 |
| 155 | Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 470-7 | 9.7 | 160 |
| 154 | Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. <i>Medical Care</i> , 2011 , 49, 427-35 | 3.1 | 42 |
| 153 | Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: results from the Women's Health Initiative Memory Study. <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 107-12 | 5.6 | 59 |
| 152 | Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer. <i>Journal of the American Dietetic Association</i> , 2011 , 111, 56-66 | | 9 |
| 151 | Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Causes and Control</i> , 2011 , 22, 1415-24 | 2.8 | 16 |
| 150 | Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. <i>Cancer</i> , 2011 , 117, 3252-61 | 6.4 | 48 |
| 149 | Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. <i>Cancer Prevention Research</i> , 2011 , 4, 840-50 | 3.2 | 43 |

| | | | |
|-----|--|------|-----|
| 148 | Dietary glycemic load, glycemic index, and carbohydrate and risk of breast cancer in the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2011 , 63, 899-907 | 2.8 | 45 |
| 147 | Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1305-14 | 27.4 | 381 |
| 146 | Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 454-63 | 4 | 134 |
| 145 | Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1368-78 | 4 | 24 |
| 144 | Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1469-75 | 9.7 | 44 |
| 143 | Physical activity and survival in postmenopausal women with breast cancer: results from the women's health initiative. <i>Cancer Prevention Research</i> , 2011 , 4, 522-9 | 3.2 | 210 |
| 142 | Breast Cancer in Postmenopausal Women After Hormone Therapy Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 466 | 27.4 | |
| 141 | Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 562-70 | 9.7 | 75 |
| 140 | Oral bisphosphonate use and breast cancer incidence in postmenopausal women. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3582-90 | 2.2 | 162 |
| 139 | Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1413-21 | 9.7 | 84 |
| 138 | Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial. <i>Clinical Trials</i> , 2010 , 7, 744-8 | 2.2 | 9 |
| 137 | Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1684-92 | 27.4 | 391 |
| 136 | Alcohol consumption and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2066-72 | 4 | 10 |
| 135 | Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1422-31 | 9.7 | 101 |
| 134 | Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2690-7 | 2.2 | 31 |
| 133 | Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 74-9 | 4 | 18 |
| 132 | Bisphosphonates for breast cancer therapy and prevention?. <i>IBMS BoneKEy</i> , 2010 , 7, 364-368 | | |
| 131 | Lung cancer and hormone replacement therapy [Authors' reply]. <i>Lancet, The</i> , 2010 , 375, 118-119 | 40 | 1 |

| | | | |
|-----|--|------|-----|
| 130 | Performance of common genetic variants in breast-cancer risk models. <i>New England Journal of Medicine</i> , 2010 , 362, 986-93 | 59.2 | 334 |
| 129 | Dietary vitamin D and calcium intake and mammographic density in postmenopausal women. <i>Menopause</i> , 2010 , 17, 1152-60 | 2.5 | 15 |
| 128 | Hormone therapy suspension and mammography in Women's Health Initiative clinical trials. <i>Annals of Internal Medicine</i> , 2010 , 152, 133 | 8 | |
| 127 | Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Causes and Control</i> , 2010 , 21, 2173-81 | 2.8 | 7 |
| 126 | New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. <i>Archives of Internal Medicine</i> , 2009 , 169, 1684-91 | | 15 |
| 125 | American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3235-58 | 2.2 | 223 |
| 124 | Aromatase inhibitor-associated arthralgias. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4932-4 | 2.2 | 30 |
| 123 | Breast cancer after use of estrogen plus progestin in postmenopausal women. <i>New England Journal of Medicine</i> , 2009 , 360, 573-87 | 59.2 | 345 |
| 122 | Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. <i>American Journal of Clinical Nutrition</i> , 2009 , 90, 162-97 | | 66 |
| 121 | Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6135-43 ² | 2.2 | 52 |
| 120 | Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3079-85 | 4 | 51 |
| 119 | American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 986-93 | 2.2 | 50 |
| 118 | Caution regarding 25-hydroxyvitamin D monitoring in women with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, e72-3; author reply e74 | 2.2 | 5 |
| 117 | Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. <i>Clinical Breast Cancer</i> , 2009 , 9, 219-24 | 3 | 17 |
| 116 | Implementing a low-fat eating plan in the Women's Intervention Nutrition Study. <i>Journal of the American Dietetic Association</i> , 2009 , 109, 688-96 | | 39 |
| 115 | Menopausal hormone therapy, hormone receptor status, and lung cancer in women. <i>Seminars in Oncology</i> , 2009 , 36, 566-71 | 5.5 | 21 |
| 114 | Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. <i>Breast</i> , 2009 , 18 Suppl 2, S1-11 | 3.6 | 31 |
| 113 | Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2009 , 125, 2704-10 | 7.5 | 120 |

| | | | |
|-----|--|------|-----|
| 112 | A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 339-50 | 4.4 | 25 |
| 111 | Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. <i>Breast Cancer Research and Treatment</i> , 2009 , 118, 81-7 | 4.4 | 79 |
| 110 | A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). <i>Nature Genetics</i> , 2009 , 41, 579-84 | 36.3 | 452 |
| 109 | Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. <i>Lancet, The</i> , 2009 , 374, 1243-51 | 4.0 | 219 |
| 108 | Influence of stressors on breast cancer incidence in the Women's Health Initiative. <i>Health Psychology</i> , 2009 , 28, 137-46 | 5 | 67 |
| 107 | Early breast and prostate cancer and clinical outcomes (fracture). <i>Oncology</i> , 2009 , 23, 16-20 | 1.8 | 4 |
| 106 | Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial. <i>Clinical Breast Cancer</i> , 2008 , 8, 343-6 | 3 | 4 |
| 105 | Calcium plus vitamin D supplementation and the risk of breast cancer. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1581-91 | 9.7 | 332 |
| 104 | Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1036-45 | 27.4 | 279 |
| 103 | Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4875-82 | 2.2 | 376 |
| 102 | Estrogen plus progestin and risk of benign proliferative breast disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2337-43 | 4 | 29 |
| 101 | Adherence to oral endocrine therapy for breast cancer: a nursing perspective. <i>Clinical Journal of Oncology Nursing</i> , 2008 , 12, 213-21 | 1.1 | 40 |
| 100 | Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. <i>American Journal of Epidemiology</i> , 2008 , 167, 1207-16 | 3.8 | 111 |
| 99 | Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. <i>Archives of Internal Medicine</i> , 2008 , 168, 370-7; quiz 345 | | 65 |
| 98 | Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. <i>American Journal of Epidemiology</i> , 2008 , 168, 158-69 | 3.8 | 73 |
| 97 | Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 563-71 | 9.7 | 46 |
| 96 | Low-fat dietary pattern and risk of benign proliferative breast disease: a randomized, controlled dietary modification trial. <i>Cancer Prevention Research</i> , 2008 , 1, 275-84 | 3.2 | 13 |
| 95 | Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. <i>American Journal of Epidemiology</i> , 2008 , 167, 1407-15 | 3.8 | 111 |

| | | | |
|----|---|------|-----|
| 94 | Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2609-18 | 4 | 76 |
| 93 | Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. <i>Menopause</i> , 2008 , 15, 804-9 | 2.5 | 3 |
| 92 | Colorectal Cancer in Women After Stopping Postmenopausal Hormone TherapyReply. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 2744 | 27.4 | |
| 91 | Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 112 Suppl 1, 25-34 | 4.4 | 31 |
| 90 | Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. <i>Cancer</i> , 2008 , 113, 907-15 | 6.4 | 66 |
| 89 | Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast. <i>International Journal of Cancer</i> , 2007 , 121, 1346-51 | 7.5 | 17 |
| 88 | National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. <i>Clinical Breast Cancer</i> , 2007 , 7, 895-900 | 3 | 19 |
| 87 | Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative. <i>Cancer Causes and Control</i> , 2007 , 18, 431-8 | 2.8 | 10 |
| 86 | Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1534-43 | 9.7 | 160 |
| 85 | The decrease in breast-cancer incidence in 2003 in the United States. <i>New England Journal of Medicine</i> , 2007 , 356, 1670-4 | 59.2 | 738 |
| 84 | Predicting risk of breast cancer in postmenopausal women by hormone receptor status. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1695-705 | 9.7 | 103 |
| 83 | Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007 , 14, 169-87 | 5.7 | 141 |
| 82 | Lifestyle change including dietary fat reduction and breast cancer outcome. <i>Journal of Nutrition</i> , 2007 , 137, 233S-235S | 4.1 | 17 |
| 81 | Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2006 , 118, 1292-301 | 7.5 | 33 |
| 80 | Adherence to endocrine therapy for breast cancer. <i>Oncology</i> , 2006 , 71, 1-9 | 3.6 | 256 |
| 79 | Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. <i>Current Medical Research and Opinion</i> , 2006 , 22, 1575-85 | 2.5 | 27 |
| 78 | Statin use and breast cancer: prospective results from the Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 700-7 | 9.7 | 146 |
| 77 | Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 655-66 | 27.4 | 738 |

| | | | |
|----|--|------|------|
| 76 | Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1647-57 | 27.4 | 410 |
| 75 | Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 643-54 | 27.4 | 283 |
| 74 | Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 629-42 | 27.4 | 553 |
| 73 | Low-Fat Diet and Risk of Breast Cancer Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 278 | 27.4 | 3 |
| 72 | The association between aspirin use and the incidence of colorectal cancer in women. <i>American Journal of Epidemiology</i> , 2006 , 164, 567-75 | 3.8 | 29 |
| 71 | Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1767-76 | 9.7 | 633 |
| 70 | Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>New England Journal of Medicine</i> , 2006 , 354, 684-96 | 59.2 | 772 |
| 69 | Calcium plus vitamin D supplementation and the risk of fractures. <i>New England Journal of Medicine</i> , 2006 , 354, 669-83 | 59.2 | 1366 |
| 68 | Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. <i>Maturitas</i> , 2006 , 55, 103-15 | 5 | 177 |
| 67 | Abnormal mammographic findings with short-interval follow-up recommendation. <i>Clinical Breast Cancer</i> , 2005 , 6, 235-9 | 3 | 4 |
| 66 | Progestins and recurrence in breast cancer survivors. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 471-2 | 9.7 | 10 |
| 65 | Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1366-76 | 9.7 | 207 |
| 64 | Ethnicity and breast cancer: factors influencing differences in incidence and outcome. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 439-48 | 9.7 | 471 |
| 63 | RESPONSE: Re: Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1619-1620 | 9.7 | 3 |
| 62 | Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 1701-12 | 27.4 | 3160 |
| 61 | Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4507-13 | 2.2 | 35 |
| 60 | Estrogen plus progestin and colorectal cancer in postmenopausal women. <i>New England Journal of Medicine</i> , 2004 , 350, 991-1004 | 59.2 | 496 |
| 59 | Menopausal hormone therapy after breast cancer. <i>Lancet, The</i> , 2004 , 363, 410-1 | 40 | 20 |

| | | | |
|----|--|------|------|
| 58 | American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2597-9 | 2.2 | 70 |
| 57 | Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. <i>Seminars in Oncology</i> , 2003 , 30, 776-88 | 5.5 | 24 |
| 56 | Research staff turnover and participant adherence in the Women's Health Initiative. <i>Contemporary Clinical Trials</i> , 2003 , 24, 422-35 | | 12 |
| 55 | Meta-analysis of vascular and neoplastic events associated with tamoxifen. <i>Journal of General Internal Medicine</i> , 2003 , 18, 937-47 | 4 | 286 |
| 54 | HT and breast cancer risk. <i>Sexuality, Reproduction & Menopause</i> , 2003 , 1, 15-18 | | 1 |
| 53 | The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. <i>Annals of Epidemiology</i> , 2003 , 13, S87-97 | 6.4 | 155 |
| 52 | Differences between estimated caloric requirements and self-reported caloric intake in the women's health initiative. <i>Annals of Epidemiology</i> , 2003 , 13, 629-37 | 6.4 | 45 |
| 51 | American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4042-57 | 2.2 | 812 |
| 50 | Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 3243-53 | 27.4 | 1294 |
| 49 | Frequency and predictive value of a mammographic recommendation for short-interval follow-up. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 429-36 | 9.7 | 74 |
| 48 | Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. <i>Cancer Research</i> , 2003 , 63, 6096-101 | 10.1 | 239 |
| 47 | Weight loss in breast cancer patient management. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1128-43 | 2.2 | 457 |
| 46 | Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). <i>Cancer Causes and Control</i> , 2002 , 13, 741-51 | 2.8 | 393 |
| 45 | American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3328-43 | 2.2 | 166 |
| 44 | The effects of tamoxifen and estrogen on brain metabolism in elderly women. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 592-7 | 9.7 | 76 |
| 43 | American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3317-27 | 2.2 | 196 |
| 42 | Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model. <i>Medical Decision Making</i> , 2002 , 22, 386-93 | 2.5 | 8 |
| 41 | Breast cancer risk reduction: strategies for women at increased risk. <i>Annual Review of Medicine</i> , 2002 , 53, 519-40 | 17.4 | 28 |

| | | | |
|----|---|------|-----|
| 40 | Trends in Prostate and Breast Cancer Clinical Research as Reported in the American Society of Clinical Oncology Proceedings. <i>Prostate Journal</i> , 2001 , 3, 26-29 | | |
| 39 | American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1378-91 | 2.2 | 296 |
| 38 | Reducing the risk of breast cancer. <i>New England Journal of Medicine</i> , 2000 , 343, 191-8 | 59.2 | 49 |
| 37 | Tamoxifen for treatment of premenopausal women with breast cancer. <i>Cancer Investigation</i> , 2000 , 18, 681-4 | 2.1 | |
| 36 | Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 130-42 | 2.2 | 32 |
| 35 | American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1939-55 | 2.2 | 139 |
| 34 | Monitoring dietary change in a low-fat diet intervention study: advantages of using 24-hour dietary recalls vs food records. <i>Journal of the American Dietetic Association</i> , 1996 , 96, 574-9 | | 128 |
| 33 | Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. <i>Cancer</i> , 1996 , 78, 2119-26 | 6.4 | 51 |
| 32 | Altered metabolism and mortality in patients with colon cancer receiving chemotherapy. <i>American Journal of the Medical Sciences</i> , 1995 , 310, 48-55 | 2.2 | 7 |
| 31 | Dietary intake and counseling, weight maintenance, and the course of HIV infection. <i>Journal of the American Dietetic Association</i> , 1995 , 95, 428-32; quiz 433-5 | | 61 |
| 30 | 5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. <i>Investigational New Drugs</i> , 1994 , 12, 57-63 | 4.3 | 21 |
| 29 | The scope of nutrition intervention trials with cancer-related endpoints. <i>Cancer</i> , 1994 , 74, 2734-8 | 6.4 | 25 |
| 28 | New directions in the nutritional management of the cancer patient. <i>Nutrition Research</i> , 1993 , 13, 3-21 | 4 | 14 |
| 27 | Breast cancer chemoprevention. Tamoxifen: current issues and future prospective. <i>Cancer</i> , 1993 , 72, 1032-7 | 6.4 | 31 |
| 26 | The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1993 , 27, 253-62 | 4.4 | 80 |
| 25 | Metabolic response to chemotherapy in colon cancer patients. <i>Journal of Parenteral and Enteral Nutrition</i> , 1992 , 16, 65S-71S | 4.2 | 9 |
| 24 | Unpublished Data Summaries and the design and conduct of clinical trials. The Nutrition Adjuvant Study experience and commentary. <i>Contemporary Clinical Trials</i> , 1989 , 10, 368-77 | | 8 |
| 23 | Mitoxantrone use in breast cancer patients with elevated bilirubin. <i>Breast Cancer Research and Treatment</i> , 1989 , 14, 267-74 | 4.4 | 4 |

| | | | |
|----|---|------|-----|
| 22 | Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. <i>Cancer</i> , 1989 , 63, 330-4 | 6.4 | 144 |
| 21 | A breast cancer Nutrition Adjuvant Study (NAS): protocol design and initial patient adherence. <i>Breast Cancer Research and Treatment</i> , 1987 , 10, 21-9 | 4.4 | 36 |
| 20 | Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. <i>Cancer</i> , 1987 , 59, 406-10 | 6.4 | 55 |
| 19 | Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. <i>Cancer</i> , 1986 , 58, 183-6 | 6.4 | 78 |
| 18 | Pathophysiology of malnutrition in the adult cancer patient. <i>Cancer</i> , 1986 , 58, 1867-73 | 6.4 | 64 |
| 17 | Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. <i>Breast Cancer Research and Treatment</i> , 1986 , 7, 23-30 | 4.4 | 110 |
| 16 | Metabolic abnormalities in cancer patients: carbohydrate metabolism. <i>Surgical Clinics of North America</i> , 1986 , 66, 957-68 | 4 | 40 |
| 15 | Pathophysiology of malnutrition in the adult cancer patient. <i>Cancer</i> , 1986 , 58, 1867-1873 | 6.4 | 43 |
| 14 | Metabolic abnormalities in the cancer patient. <i>Cancer</i> , 1985 , 55, 225-9 | 6.4 | 87 |
| 13 | Critical evaluation of the role of nutritional support with chemotherapy. <i>Cancer</i> , 1985 , 55, 268-72 | 6.4 | 34 |
| 12 | Influence of nutritional status on circulatory ribonuclease C levels in patients with cancer. <i>Cancer</i> , 1985 , 55, 427-31 | 6.4 | 2 |
| 11 | Significance of altered nutritional status in acquired immune deficiency syndrome (AIDS). <i>Nutrition and Cancer</i> , 1985 , 7, 85-91 | 2.8 | 69 |
| 10 | Vitamin K in the treatment of cancer. <i>Cancer Treatment Reviews</i> , 1985 , 12, 49-63 | 14.4 | 47 |
| 9 | Differential pulse polarographic determination of plasma menadione. <i>Analytical Biochemistry</i> , 1984 , 141, 488-93 | 3.1 | 15 |
| 8 | Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. <i>Cancer</i> , 1984 , 53, 2701-6 | 6.4 | 135 |
| 7 | Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial. <i>Cancer</i> , 1983 , 52, 606-9 | 6.4 | 6 |
| 6 | Dosimetry and preliminary human studies of ¹⁸ F-5-fluorouracil. <i>International Journal of Nuclear Medicine and Biology</i> , 1982 , 9, 25-35 | | 26 |
| 5 | Factors influencing the interim interpretation of a breast cancer trial: danger of achieving the "expected" result. <i>Contemporary Clinical Trials</i> , 1981 , 2, 123-32 | | 6 |

| | | | |
|---|---|-----|----|
| 4 | Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. <i>Cancer</i> , 1981 , 48, 1088-95 | 6.4 | 33 |
| 3 | Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery. <i>Cancer</i> , 1981 , 48, 1711-4 | 6.4 | 12 |
| 2 | Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. <i>Cancer</i> , 1980 , 45, 2240-4 | 6.4 | 17 |
| 1 | Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. <i>Cancer</i> , 1978 , 42, 2546-52 | 6.4 | 41 |